66 related articles for article (PubMed ID: 8681493)
1. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
Kleinbloesem CH; Jaquet-Müller F; al-Hamdan Y; Baldauf C; Gisclon L; Wesnes K; Curtin CR; Stubbs RJ; Walker SA; Brunner-Ferber F
Clin Pharmacol Ther; 1996 Jun; 59(6):675-85. PubMed ID: 8681493
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
4. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
7. Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats.
Caldwell GW; Wu WN; McKown LA; Diane Gauthier A; Masucci JA; Jones WJ; Leo GC; Reitz AB
J Pharm Biomed Anal; 2006 May; 41(2):500-9. PubMed ID: 16386397
[TBL] [Abstract][Full Text] [Related]
8. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
9. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
Miceli JJ; Wilner KD; Swan SK; Tensfeldt TG
J Clin Pharmacol; 2005 Jun; 45(6):620-30. PubMed ID: 15901743
[TBL] [Abstract][Full Text] [Related]
12. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
Parker JD; Bart BA; Webb DJ; Koren MJ; Siegel RL; Wang H; Malhotra B; Jen F; Glue P
Crit Care Med; 2007 Aug; 35(8):1863-8. PubMed ID: 17522570
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
[TBL] [Abstract][Full Text] [Related]
14. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
Hallam KT; Olver JS; McGrath C; Norman TR
Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
16. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
17. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies--Part I.
Saletu B; Grünberger J; Linzmayer L; Dubini A
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):489-95. PubMed ID: 6139346
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of the antipsychotic agent, mazapertine, in dog--mass spectral characterization and identification of metabolites.
Wu WN; McKown LA; Takacs AR; Jones WJ; Reitz AB
Xenobiotica; 1999 May; 29(5):453-66. PubMed ID: 10379984
[TBL] [Abstract][Full Text] [Related]
19. Postural hypotension in chronically medicated schizophrenics.
Silver H; Kogan H; Zlotogorski D
J Clin Psychiatry; 1990 Nov; 51(11):459-62. PubMed ID: 1977739
[TBL] [Abstract][Full Text] [Related]
20. Metabolic fate of the antipsychotic agent, mazapertine, in man--API-MS and MS/MS identification of urinary metabolites.
Wu WN; McKown LA; Reitz AB
Eur J Drug Metab Pharmacokinet; 2007; 32(3):171-6. PubMed ID: 18062409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
